BDX

Business profile & competitive position

Becton, Dickinson and Company (BDX) sits in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products used by hospitals, physicians, clinical laboratories, pharmaceutical companies, life-science researchers, and consumers. Its solution areas include medication management and patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology, infectious-disease and cancer diagnostics, and cellular research.

As of September 30, 2025, BD reported operating through three worldwide segments: BD Medical, BD Life Sciences, and BD Interventional. The current margin profile, however, does not point to a strong competitive moat on a trailing basis. Net margin is 4.5% and return on equity is 3.8%. A 3.8% ROE is modest relative to typical equity-cost assumptions, suggesting the business is not presently converting its revenue base into high shareholder returns. The low beta of 0.28 confirms stable, defensive demand, but it does not, by itself, indicate pricing power. Rather, the combination of thin profitability and a high valuation implies investors are looking for margin recovery and portfolio reorganization rather than paying for an already-wide moat.

Financial posture

BDX carries a market capitalization of $50.6 billion and trades at a P/E of 55.4. That multiple is steep relative to the current net margin of 4.5% and ROE of 3.8%. A P/E above 55 typically embeds expectations of meaningful earnings growth or margin repair, while the 4.5% net margin shows the business is not yet delivering that level of profitability. The beta of 0.28 positions the stock as defensive in market terms, consistent with the non-discretionary nature of much medical supply demand. In sum, the valuation is pricing in a transformation story; the income-statement metrics show the work is still ahead.

Strategic priorities & outlook

BD’s most recent 10-K outlines a company being actively reshaped. Effective October 1, 2025, BD reorganized into five separately managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.

A central transaction is the Reverse Morris Trust combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation. BD expects the deal to close around the end of the first quarter of calendar 2026 and to receive roughly $4 billion in cash; BD shareholders would own approximately 39.2% of the combined company. At the same time, BD closed the $3.914 billion acquisition of Edwards Lifesciences’ Critical Care product group in September 2024, integrating it as BD Advanced Patient Monitoring within BD Medical.

On the footprint side, BD manufactures in 18 countries outside the United States across EMEA, Greater Asia, Latin America, and Canada. The filing notes that foreign-exchange fluctuations have caused foreign-revenue profitability to swing more than domestic profitability, and that non-U.S. activities carry greater operational risk. Past divestitures include the Diabetes Care business (Embecta Corp.) in April 2022 and the August 2023 sale of the Interventional segment’s Surgical Instrumentation platform, which produced a pre-tax gain of approximately $268 million.

Macro & geopolitical exposure

Because BD operates in Medical - Instruments & Supplies, its exposures are those standard to the industry. Hospital and physician purchasing cycles, reimbursement rates, and regulatory requirements are core variables. The product set is FDA-regulated, and many devices face EU MDR and other global compliance obligations. Supply-chain inputs such as plastics, resins, electronic components, and sterilization capacity can affect costs and availability. With manufacturing in 18 non-U.S. countries, the company is exposed to currency translation, cross-border tariffs, and trade-policy shifts. Public-health funding and diagnostic demand can also move with government budgets and disease-prevalence trends. Demographic aging supports underlying procedure volume, but that tailwind does not override reimbursement, regulatory, or FX pressures.

Recent developments

Recent headlines show both capital-markets recognition and internal digital investment. On September 26, 2026, Seeking Alpha included BD in “Best Dividend Kings: September 2026,” and on September 18, 2026, it ranked BD among “The Dividend Kings Ranked By Quality Scores.” On September 25, 2026, Defense World reported that Engineers Gate Manager LP had bought new shares in Becton, Dickinson and Company. On September 21, 2026, PR Newswire announced that Arthur Hu will join BD as Chief Information and Digital Officer, signaling continued investment in data, automation, and digital operations.

Earnings behavior & post-earnings drift

BDX has beaten earnings estimates in all eight of the last reported quarters, a 100% beat rate, with an average earnings surprise of 8.2%. The average five-day price move after those reports is 3.66%, classified as an upward post-earnings drift.

The most recent four quarters illustrate that beats do not guarantee immediate gains. On August 6, 2026, BD reported EPS of $3.23 against an estimate of $3.14, a 2.9% surprise; the stock fell 0.12% the next day but drifted up 2.77% over the following five days. On May 7, 2026, EPS of $2.90 beat the $2.78 estimate by 4.3%, yet the stock dropped 2.5% the next session and was down 5.74% over five days. On February 9, 2026, EPS of $2.91 crushed the $2.21 estimate by 31.7%, producing a 5.3% next-day gain and 8.8% five-day gain. On November 6, 2025, EPS of $3.96 edged past the $3.92 estimate by 1.0%, with the stock up 0.25% the next day and 8.82% over five days. The next scheduled report is November 5, 2026, before the open, with the market’s real expectation at $4.06.

The pattern suggests that while BD consistently exceeds the official consensus, the magnitude of the beat, guidance commentary, and segment-margin detail drive whether the market rewards the report in the following days.

To form a fuller view of BDX’s risk/reward profile, readers should explore the complete institutional verdict, including consensus rating trends, detailed segment estimates, and the latest模型.